Abstract
AbstractAlpha-thalassemia is an autosomal recessive monogenic disease with increasing worldwide prevalence. The molecular basis is due to mutation or deletion of one or more duplicated α-globin genes, and disease severity is directly related to the number of allelic copies compromised. The most severe form, α-thalassemia major (αTM), results from loss of all four copies of α-globin and has historically resulted in fatalityin utero. However, the advent ofin uterotransfusions now enables the survival of an increasing number of children with αTM. Postnatally, patients face challenges similar to β-thalassemia, including severe anemia and erythrotoxicity due to an imbalance of β-globin and α-globin chains. Hematopoietic stem cell transplantation (HSCT) as a therapeutic option is limited by donor availability and potential transplant-related complications. Despite progress in genome editing treatments for β-thalassemia, there is no analogous curative option for patients suffering from α-thalassemia. To address this, we designed a novel Cas9/AAV6-mediated genome editing strategy that integrates a functional α-globin gene into the β-globin locus in αTM patient-derived hematopoietic stem and progenitor cells (HSPCs). Incorporation of a truncated erythropoietin receptor transgene into the α-globin integration cassette dramatically increased erythropoietic output from edited HSPCs and led to the most robust production of α-globin, and consequently normal hemoglobin. By directing edited HSPCs toward increased production of clinically relevant RBCs instead of other divergent cell types, this approach has the potential to mitigate the limitations of traditional HSCT for the hemoglobinopathies, including low genome editing and low engraftment rates. These findings support development of a definitiveex vivoautologous genome editing strategy that may be curative for α-thalassemia.
Publisher
Cold Spring Harbor Laboratory